Aaron Lisberg, MD
- Thoracic Medical Oncology
About
Clinical Summary:
Dr. Aaron Lisberg is a thoracic medical oncologist at the University of California, Los Angeles (UCLA). He specializes in novel drug development, antibody drug conjugates (ADCs), immunotherapy, and metabolically targeted therapies in patients with advanced malignancies, with a specific focus on lung cancer. He is board certified in hematology and medical oncology.
Dr. Lisberg received his medical degree from the University of Minnesota Medical School, where he was elected to the AOA honor society. He then completed his internal medicine residency at The University of Washington in Seattle, followed by his hematology/oncology fellowship at UCLA.
Research Summary:
Dr. Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies, with a specific focus on lung cancer. He has a wide range of ongoing research projects including evaluation of factors predictive of response or toxicity to antibody drug conjugates (ADCs) and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumor alterations. He is also the clinical PI and Sub-I of several clinical trials evaluating novel therapeutics in a variety of malignancies, including Phase I, II, and III assessments.
Languages
Education
Medical Board Certifications
Fellowship
Residency
Internship
Degree
Locations
Hospital Affiliations
Ronald Reagan UCLA Medical Center
UCLA Santa Monica Medical Center
Medical Services
Areas of Focus
Research
Interests
Research Summary:
Dr. Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies, with a specific focus on lung cancer. He has a wide range of ongoing research projects including evaluation of factors predictive of response or toxicity to antibody drug conjugates (ADCs) and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumor alterations. He is also the clinical PI and Sub-I of several clinical trials evaluating novel therapeutics in a variety of malignancies, including Phase I, II, and III assessments.
Publications
Brief summary of publications, as follows:
- Velez MA, Tsai HHC, Shackelford DB, Garon EB, Lisberg A. Lung Cancer. 2022 Apr;166:253-254. doi: 10.1016/j.lungcan.2021.12.001. Epub 2021 Dec 24. PubMed PMID: 35031176.
- Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. Lung Cancer. 2021 Nov;161:34-41. doi: 10.1016/j.lungcan.2021.08.009. Epub 2021 Aug 30. PubMed PMID: 34507111; PubMed Central PMCID: PMC8923054.
- Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. PubMed PMID: 29874546; PubMed Central PMCID: PMC6063769.
- Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. Cancer Immunol Res. 2018 Mar;6(3):288-294. doi: 10.1158/2326-6066.CIR-17-0063. Epub 2018 Jan 30. PubMed PMID: 29382669; PubMed Central PMCID: PMC6066474.
- Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. PubMed PMID: 28551359; PubMed Central PMCID: PMC5538772.
- Zhou N, Velez MA, Owen D, Lisberg AE. J Natl Compr Canc Netw. 2020 Sep;18(9):1287-1290. doi: 10.6004/jnccn.2020.7640. PubMed PMID: 32886906.
- Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21. PubMed PMID: 31113840; PubMed Central PMCID: PMC6901027.
- Lisberg A, Garon EB. JAMA Oncol. 2016 May 1;2(5):571-572. doi: 10.1001/jamaoncol.2016.0043. PubMed PMID: 26986923.
- Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Nature. 2002 Jul 4;418(6893):41-9. doi: 10.1038/nature00870. Epub 2002 Jun 20. PubMed PMID: 12077603.
- Lisberg A, Garon EB. J Clin Oncol. 2019 Mar 1;37(7):529-536. doi: 10.1200/JCO.18.01534. Epub 2019 Jan 24. PubMed PMID: 30676857.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.